Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN) research hub
4 indexed studies · 1 currently recruiting
- ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
This study is testing a new medicine, BMS-986288, alone and with another drug, nivolumab. It's for people with various advanced cancers. The main goals are to check for side effects and how well the new medicine works against the cancer.
Spain · France · Italy - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS
This study is testing a new treatment called Oncobax®-AK, given alongside established immunotherapy drugs, for people with advanced lung or kidney cancer. It's looking for the safest dose and early signs of how well it works. This is an early-stage trial, focusing on safety.
Belgium · France - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
This study looks at a new combination treatment for advanced kidney cancer that has grown despite earlier immune-boosting treatment. Researchers want to see if combining two drugs, Atezolizumab and Cabozantinib, works better than Cabozantinib alone to control the cancer and help people live longer.
Poland · Germany - recruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
United States · Australia · Austria